References
- 1. S. A. Thomas, Anti-HIV drug distribution to the central nervous system, Curr. Pharm. Des.10 (2004) 1313–1324; DOI: 10.2174/1381612043384835.
- 2. J. A. Zastre, G. N. Chan, P. T. Ronaldson, M. Ramaswamy, P. O. Couraud, I. A. Romero, B. Weksler, M. Bendayan and R. Bendayan, Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line, J. Neurosci. Res.87 (2009) 1023–1036; DOI: 10.1002/jnr.21898.
- 3. M. Ahn, S. Ghaemmaghami, Y. Huang, P. W. Phuan, B. C. May, K. Giles, S. J. DeArmond and S. B. Prusiner, Pharmacokinetics of quinacrine efflux from mouse brain via the P-glycoprotein efflux transporter, PLoS One 7 (2012) e39112; DOI: 10.1371/journal.pone.0039112.
- 4. D. Pal, D. Kwatra, M. Minocha, D. K. Paturi, B. Budda and A. K. Mitra, Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals, Life Sci.88 (2011) 959–971; DOI: 10.1016/j.lfs.2010.09.012.
- 5. A. Antinori, G. Arendt, J. T. Becker, B. J. Brew, D. A. Byrd, M. Cherner, D. B. Clifford, P. Cinque, L. G. Epstein, K. Goodkin, M. Gisslen, I. Grant, R. K. Heaton, J. Joseph, K. Marder, C. M. Marra, J. C. McArthur, M. Nunn, R. W. Price, L. Pulliam, K. R. Robertson, N. Sacktor, V. Valcour and V. E. Wojna, Updated research nosology for HIV-associated neurocognitive disorders, Neurology69 (2007) 1789–1799; DOI: 10.1212/01.WNL.0000287431.88658.8b.
- 6. L. Varatharajan and S. A. Thomas, The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research, Antiviral Res.82 (2009) A99–A109; DOI: 10.1016/j.antiviral.2008.12.013.
- 7. J. W. Polli, J. L. Jarrett, S. D. Studenberg, J. E. Humphreys, S. W. Dennis, K. R. Brouwer and J. L. Woolley, Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor, Pharm. Res.16 (1999) 1206–1212; DOI: 10.1023/A:1018941328702.
- 8. E. F. Choo, B. Leake, C. Wandel, H. Imamura, A. J. Wood, G. R. Wilkinson and R. B. Kim, Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes, Drug Metab. Dispos.28 (2000) 655–60.
- 9. S. Park and P. J. Sinko, P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice, J. Pharmacol. Exp. Ther.312 (2005) 1249–1256; DOI:10.1124/jpet.104.076216.
- 10. C. J. Bachmeier, T. J. Spitzenberger, W. F. Elmquist and D. W. Miller, Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood–brain barrier, Pharm. Res.22 (2005) 1259–1268; DOI: 10.1007/s11095-005-5271-y.
- 11. M. Hamidi, Role of P-glycoprotein in tissue uptake of indinavir in rat, Life Sci.79 (2006) 991–998; DOI: 10.1016/j.lfs.2006.05.010.
- 12. U. Roy, C. Bulot, K. Höner zu Bentrup and D. Mondal, Specific increase in MDR1 mediated drug-efflux in human brain endothelial cells following co-exposure to HIV-1 and saquinavir, PLoS One8 (2013) e75374; DOI: 10.1371/journal.pone.0075374.
- 13. Z. Binkhathlan and A. Lavasanifar, P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives, Curr. Cancer Drug Targets13 (2013) 326–346; DOI: 10.2174/15680096113139990076.
- 14. A. Palmeira, E. Sousa, M. H. Vasconcelos and M. M. Pinto, Three decades of P-gp inhibitors: skimming through several generations and scaffolds, Curr. Med. Chem.19 (2012) 1946–2025; DOI: 10.2174/092986712800167392.
- 15. H. A. Namanja, D. Emmert, D. A. Davis, C. Campos, D. S. Miller, C. A. Hrycyna and J. Chmielewski, Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers, J. Am. Chem. Soc.134 (2012) 2976–2980; DOI: 10.1021/ja206867t.
- 16. M. T. Sheu, Y. B. Liou, Y. H. Kao, Y. K. Lin and H. O. Ho, A quantitative structure-activity relationship for the modulation effects of flavonoids on p-glycoprotein-mediated transport, Chem. Pharm. Bull. (Tokyo) 58 (2010) 1187–1194; DOI: 10.1248/cpb.58.1187.
- 17. P. Limtrakul, O. Khantamat and K. Pintha, Inhibition of P-glycoprotein function and expression by kaempferol and quercetin, J. Chemother.17 (2005) 86–95; DOI: 10.1179/joc.2005.17.1.86.
- 18. D. Pal and A. K. Mitra, MDR- and CYP3A4-mediated drug-herbal interactions, Life Sci.78 (2006) 2131–2145; DOI: 10.1016/j.lfs.2005.12.010.
- 19. J. Patel, B. Buddha, S. Dey, D. Pal and A. K. Mitra, In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity, Am. J. Ther.11 (2004) 262–277.
- 20. S. Zhou, X. Feng, P. Kestell, J. W. Paxton, B. C. Baguley and E. Chan, Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells, Eur. J. Pharm. Sci.24 (2005) 513–524; DOI: 10.1016/j.ejps.2005.01.006.
- 21. X.Y. Yu, S. G. Lin, Z. W. Zhou, X. Chen, J. Liang, X. Q. Yu, B. Chowbay, J. Y. Wen, W. Duan, E. Chan, X.T. Li, J. Cao, C. G. Li, C. C. Xue and S. F. Zhou, Role of P-glycoprotein in limiting the brain penetration of glabridin, an active isoflavan from the root of Glycyrrhiza glabra, Pharm. Res.24 (2007) 1668–1690; DOI: 10.1007/s11095-007-9297-1.
- 22. Y. J. Moon and M. E. Morris, Pharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in rats, Mol. Pharm.4 (2007) 865–872; DOI: 10.1021/mp7000928.
- 23. J. G. Sarver, W. A. Klis, J. P. Byers and P. W. Erhardt, Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein, J. Biomol. Screen7 (2002) 29–34; DOI: 10.1177/108705710200700105.
- 24. K. Berginc, I. Milisav and A. Kristl, Garlic flavonoids and organosulfur compounds: Impact on the hepatic pharmacokinetics of saquinavir and darunavir, Drug Metab. Pharmacokin.25 (2010) 521–530; DOI: JST.JSTAGE/dmpk/DMPK-10-RG-053 [pii].
- 25. A. Di Pietro, G. Conseil, J. M. Pérez-Victoria, G. Dayan, H. Baubichon-Cortay, D. Trompier, E. Steinfels, J. M. Jault, H. de Wet, M. Maitrejean, G. Comte, A. Boumendjel, A. M. Mariotte, C. Dumontet, D. B. McIntosh, A. Goffeau, S. Castanys, F. Gamarro and D. Barron, Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters, Cell. Mol. Life Sci.59 (2002) 307–322; DOI: 10.1007/s00018-002-8424-8.
- 26. J. B. Vaidyanathan and T. Walle, Cellular uptake and efflux of the tea flavonoid (–)epicatechin-3-gallate in the human intestinal cell line Caco-2, J. Pharmacol. Exp. Ther.307 (2003) 745–752; DOI: 10.1124/jpet.103.054296.
- 27. Y. Li, J. L. Revalde, G. Reid and J. W. Paxton, Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer, Drug Metab. Rev.42 (2010) 590–611; DOI: 10.3109/03602531003758690.